Phase 3 B-cell Lymphoma Clinical Trials
15 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–15 of 15 trials
Recruiting
Phase 3
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Relapsed or Refractory Large B-cell Lymphoma
Kite, A Gilead Company550 enrolled2 locationsNCT07479797
Recruiting
Phase 3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals904 enrolled155 locationsNCT06091865
Recruiting
Phase 3
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaLymphoma, B-Cell+6 more
Lyell Immunopharma, Inc.400 enrolled38 locationsNCT07188558
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Mantle Cell LymphomaB-cell Lymphoma
BeOne Medicines300 enrolled152 locationsNCT06742996
Recruiting
Phase 3
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Large B-cell Lymphoma
AstraZeneca420 enrolled64 locationsNCT07215585
Recruiting
Phase 3
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed240 enrolled41 locationsNCT07409428
Recruiting
Phase 2Phase 3
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting
Phase 3
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD200 enrolled1 locationNCT07493109
Recruiting
Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
Phase 2Phase 3
Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Sun Yat-sen University80 enrolled1 locationNCT07084662
Recruiting
Phase 2Phase 3
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Karyopharm Therapeutics Inc501 enrolled57 locationsNCT04442022
Recruiting
Phase 3
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Recurrent and Refractory Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd390 enrolled1 locationNCT07011056
Recruiting
Phase 3
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc416 enrolled1 locationNCT06792253
Recruiting
Phase 3
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell LymphomaLarge B-cell Lymphoma
Universität des Saarlandes330 enrolled17 locationsNCT05820841
Recruiting
Phase 3Phase 4
Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant study
Relapsed or refractory CD20 positive diffuse large B-cell lymphoma
Roche40 enrolled1 locationACTRN12606000373572